Ratings Médica Sur, S.A.B. de C.V.

Equities

MEDICA B

MXP510121215

End-of-day quote Mexican S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
40.6 ^MXN	+1.50%		+0.50%	-0.07%

Feb. 24	Médica Sur, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
2023	Médica Sur, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Strengths

The group's high margin levels account for strong profits.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MÉDICA SUR, S.A.B. DE C.V.	-0.07%	251M	-	C+
CVS HEALTH CORPORATION	-14.89%	84.87B		B-
HCA HEALTHCARE, INC.	+12.57%	83.08B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.78%	16.72B		B
FRESENIUS SE & CO. KGAA	-3.06%	16.4B		A-
QUEST DIAGNOSTICS INCORPORATED	-2.04%	15.04B		A-
EUROFINS SCIENTIFIC SE	-3.97%	11.88B		A-
FRESENIUS MEDICAL CARE AG	-1.42%	11.88B		A-
PURE HEALTH HOLDING	-31.75%	11.86B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes